Results of the ACTION‐Galactosemia Kids Study to Evaluate the Effects of Govorestat in Pediatric Patients with Classic Galactosemia
Evan Bailey, Shoshana Shendelman(Io Therapeutics (United States)), Shane C. Quinonez(University of Michigan), Samuel Johnson(TetraLogic Pharmaceuticals (United States)), Christina Pick(TetraLogic Pharmaceuticals (United States)), Stella Wang(Hospital for Sick Children), A. Salt(TetraLogic Pharmaceuticals (United States)), Elizabeth G. Ames(University of Minnesota), Jessie Nicodemus‐Johnson(TetraLogic Pharmaceuticals (United States)), Amanda B. Pritchard(University of Michigan), Ayesha Ahmad(University of Michigan), Samuel P. Dickson(TetraLogic Pharmaceuticals (United States)), Janet A. Thomas(University of Colorado Denver), H. Phan(Rare Disease Therapeutics (United States)), Riccardo Perfetti(Inserm), Caleb W. Dayley(TetraLogic Pharmaceuticals (United States)), Suzanne Hendrix(TetraLogic Pharmaceuticals (United States))
Cited by 3
Related Papers
DJ-1 Is a Redox-Dependent Molecular Chaperone That Inhibits α-Synuclein Aggregate Formation
|PLoS Biology|2004|587
24-month intervention with a specific multinutrient in people with prodromal Alzheimer's disease (LipiDiDiet): a randomised, double-blind, controlled trial
|The Lancet Neurology|2017|244
Designing drug trials for Alzheimer's disease: What we have learned from the release of the phase III antibody trials: A report from the EU/US/CTAD Task Force
|Alzheimer s & Dementia|2013|145
Newborn screening for spinal muscular atrophy: Anticipating an imminent need
|Seminars in Perinatology|2015|79